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More than 100 different diseases are
collectively termed cancer, and each
cancer type has distinct biological and
clinical features. In addition, there
can be major differences in disease
severity and prognosis for patients
whose cancers have identical
microscopic appearances and clinical
presentations. In spite of this
complexity, there are two distinct, but
interrelated, processes that are
common to the development and
progression of all cancers. The first is
alteration of the sequence and/or
expression of cellular genes. The
second process, termed ‘clonal
selection’, is essentially an
evolutionary process promoting the
outgrowth of pre-cancerous and
cancerous cells carrying mutations
and gene expression changes that
confer the most robust proliferative
and survival properties upon the cells.
Certain gene defects are often
associated with the initial stages of a
cancer’s development and other
defects with later stages.
Nevertheless, a genetic change that
underlies tumor initiation in one
cancer type may contribute to tumor
progression in a second cancer type
and vice versa. Furthermore, each
genetic defect has a variety of effects
on the cancer’s phenotype, and
defects arising at ‘early’ stages
probably have a critical role not only
in tumor initiation but also in the
aggressive behavior of advanced
cancers. Separating out the order of
genetic changes, and the
contribution of different mutations is
not easy, but progress has been made
in identifying mutations which
underlie cancer initiation and
progression to advanced stages; and
defining the relationship between
particular gene defects and altered
phenotypic traits of cancer cells. 
Oncogenes, tumor suppressor genes
and rate-limiting mutations
The cellular genes affected by
mutation in cancer can be divided
into two classes: proto-oncogenes
and tumor suppressor genes.
Mutations in cancer cells alter the
normal structure and/or expression of
the proto-oncogene, generating
oncogenic variants (or alleles) with
altered function and/or expression.
Put simply, oncogenic alleles harbor
‘gain-of-function’ mutations that
endow them with increased or novel
functions relative to those of the
proto-oncogene alleles. By contrast,
tumor suppressor genes involved in
cancer have sustained
‘loss-of-function’ defects that
inactivate their function and/or
expression.
Recent studies have emphasized
the role in cancer of genes that
function in the repair of DNA
damage. Because these DNA repair
genes are affected by loss-of-function
mutations, they belong to the tumor
suppressor gene class. But they
probably have a more passive role in
growth regulation and cell survival
than most tumor suppressor genes.
Specifically, DNA repair gene
inactivation seems to lead to a
‘mutator phenotype’, with a resultant
increased rate of mutations in other
cellular genes. Because the
accumulation of mutations in
proto-oncogenes and tumor
suppressor genes is thought to
determine the rate of cancer
development, progression of a
pre-cancerous cell to a fully fledged
cancer cell may be greatly
accelerated by the inactivation of
DNA repair genes.
During the course of a cancer’s
development from a normal cell
through various pre-cancerous stages,
many mutations in oncogenes and
tumor suppressor genes accumulate.
The vast majority of these mutations
are somatic and present only in the
cancerous cells of the patient. Most
mutations arising in somatic cells have
little, if any, positive effect on cell
growth and survival, and many may
have detrimental or lethal effects. A
small fraction of somatic mutations
promote clonal selection by virtue of
their ability to confer improved
proliferative and survival properties.
An even smaller subset of mutations
cause not only expansion of a
pre-cancerous clone but also an
increased risk of the clone’s eventual
conversion to cancer. Mutations of
this latter type might be termed
‘rate-limiting’. Presumably, the low
frequency of mutations that can
initiate the cancer process is a critical
bottleneck delaying development of
most cancers until late in life.
After a cell has sustained a
rate-limiting mutation and therefore
passed the bottleneck, the generation
of a highly expanded population of
pre-cancerous cells is essentially
assured. Additional somatic
mutations then arise in one or more
of the pre-cancerous cells and
underlie progression to malignancy.
Inherited cancer syndromes
Only about one per cent of all
cancers arise in individuals with an
inherited cancer syndrome.
Nevertheless, studies of mutations
that underlie inherited
predisposition to cancer have
provided many insights into the
sporadic development of cancer. For
instance, the concept of rate-limiting
mutations in cancer is well illustrated
in individuals carrying inherited
mutations in the retinoblastoma
(RB1) and adenomatous polyposis
coli (APC) tumor suppressor genes. A
germline (constitutional) mutation of
one RB1 allele has no adverse
consequences per se for a mutation
carrier, although somatic inactivation
of the remaining functional RB1
allele in a developing retinoblast
initiates retinoblastoma formation.
The chance that this somatic event
will occur in one or more developing
retinoblasts of an RB1 mutation
carrier is very high, explaining why
retinal cancers arise at an early age in
nearly all those who carry a germline
RB1 mutation. Inactivation of the
RB1 gene is also critical in almost all
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non-inherited cases of
retinoblastoma, although there is
only a slight chance that both RB1
alleles will be coincidentally
inactivated by somatic mutation in a
developing retinoblast, accounting
for the rarity of retinoblastoma in the
general population.
Germline inactivation of one APC
allele in an individual with familial
polyposis predisposes to the
development of thousands of
pre-cancerous lesions in the colon
and rectum and a greatly increased
risk that one or more of these lesions
will progress to cancer. As in
retinoblastoma, somatic mutation of
the remaining functional APC allele
promotes tumor formation in
polyposis patients and APC
inactivation seems to be critical in
most sporadic colon cancers.
Intriguingly, almost all inherited
mutations are rate-limiting for the
development of only a limited range
of cancer types.
Conserved signaling pathways
Enormous progress has been made in
identifying mutations in more than
100 different oncogenes and 30
tumor suppressor genes involved in
cancer. Some mutations are unique
to cancers of a particular type,
whereas others are seen in a broad
range of cancer types. Oncogenes
and tumor suppressor genes have
diverse functions, and their protein
products can be found in almost all
subcellular compartments. In light of
the apparent heterogeneity of gene
defects in cancer, it is encouraging
that some unifying themes have
emerged. Perhaps the main theme is
that oncogenes and tumor suppressor
genes function in conserved
signaling pathways.
The retinoblastoma protein
(pRb) is regulated by the proteins
cyclin D1, cyclin-dependent kinase 4
(Cdk4) and p16 . Nearly all cancers
have inactivating mutations in the
genes encoding pRb or p16 or
activating mutations (for example,
gene amplification) in the genes
encoding cyclin D1 or Cdk4 (see
Figure 1a). Another pathway often
disrupted in cancer is the Wnt
pathway, with the most common
mutations inactivating the APC
protein or activating the β-catenin
protein (see Figure 1b). The net
consequence is that the β-catenin
protein is stabilized and its ability to
activate T-cell factor (Tcf)
transcription factors is enhanced.
A third pathway affected by
mutations in many cancers is that in
which the p53 tumor suppressor
gene functions. The p53 gene is
perhaps the single most frequently
mutated gene in cancer, and more
than 50% of all cancers harbor p53
mutations (Figure 1c). In most
cervical cancers, p53 protein
function is inhibited by the E6
proteins of certain cancer-associated
human papillomaviruses.
Other critical signaling pathways
often targeted by mutations that
cause cancer have been suggested,
including the pathway(s) in which
the epidermal growth factor receptor
(EGFR), the EGFR-related receptor
ErbB2 or HER-2, the Ras, and
probably the neurofibromatosis
type 1 (NF1) proteins function.
Gene defects in cancer progression
In spite of progress in defining
defective signaling pathways in
cancer cells, sizeable gaps need to be
closed if we hope to understand how
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Figure 1
The protein products of oncogenes (green)
and tumor suppressor genes (orange) function
in conserved signaling networks. (a) The
protein product of the RB1 gene, pRb, is
regulated by phosphorylation. When
hyperphosphorylated, pRb is unable to bind to
E2F and regulate transcription of E2F-target
genes (for example, cyclin E; dihyrofolate
reductase, DHFR; thymidylate synthase, TS;
DNA polymerase α, DNA poly α;
ribonucleotide reductase, RNR). The cyclin D1
and CDK4 proteins regulate pRb
phosphorylation. The p16 protein inhibits the
CYC D1 and CDK4 complex. (b) The APC
protein, together with glycogen synthase
kinase 3β (GSK3β), regulates β-catenin
(β-CAT) protein stability. If APC is inactivated
or if β-CAT is activated by mutation of its
N-terminus, β-CAT accumulates in the cell.
β-CAT complexes with Tcf transcription
factors, such as Tcf-4, and activates
expression of Tcf-target genes (for example,
c-MYC; cyclin D1; matrix metalloprotease 7,
MMP-7). β-CAT also functions in E-cadherin
(E-CAD) cell adhesion, linking E-CAD to the
cytoskeleton via interaction with α-catenin.
E-CAD is a tumor suppressor gene, but the
consequences of E-CAD inactivation are
distinct from that of APC inactivation or β-CAT
activation. (c) The transcription factor p53
regulates expression of genes with roles in cell
cycle control and apoptosis (for example, p21,
BAX, MDM-2) and other processes such as
angiogenesis (thrombospondin, TSP). The
stability of p53 is regulated by MDM-2, and
MDM-2 is regulated by p19Arf. In some
cancers, activating mutations in MDM-2 or
inactivation of p19Arf may have the same net
consequence as p53 inactivation. (Adapted
from Figure 2 of Haber DA, Fearon ER: Lancet
1998, 351 (suppl II):1-8.)
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the gene defects, either singly or
collectively, contribute to the cancer
phenotype. Insights are needed not
only into the ability of cancer cells to
form local masses, but also their
often lethal ability to metastasize (to
seed and grow at distant sites).
Thus far, perhaps the greatest
advances have been in defining how
the gene defects contribute to the
aberrant proliferative and survival
properties of cancer cells. Certain
oncogene and tumor suppressor gene
defects promote entry of an
otherwise non-dividing cell into the
DNA synthesis phase of the cell
cycle, often in the absence of
appropriate environmental cues for
cell division. It has also become clear
that certain gene defects abrogate
programmed cell death (apoptotic)
responses, such as those induced by
exposure of cells to hypoxic
conditions or growth-inhibiting
cytokines. Yet other alterations, such
as inactivation of DNA mismatch
repair genes, lead to a more rapid
accumulation of somatic mutations.
Unfortunately, much less is known
about the means by which specific
gene defects in cancer cells contribute
to other processes in cancer
progression, including: the ability of
cancer cells to foster new blood vessel
growth; the ability of cancer cells to
invade through physical boundaries,
such as the basement membrane of
epithelial tissues, and into lymphatics
and blood vessels; and the ability of
cancer cells to evade immune
recognition and destruction.
Recent studies have,
nevertheless, yielded some
promising clues. Cancer cells require
a continuous supply of oxygen and
nutrients and the removal of toxic
wastes for their survival and growth.
Hence, progressive growth of most
cancers, beyond a diameter of one to
two millimeters, requires
development of new blood vessels, a
process termed angiogenesis.
Angiogenesis is regulated by the net
balance of stimulatory (angiogenic)
and inhibitory (angiostatic) factors.
Intriguingly, among other mutations
in cancer, amplification and
over-expression of EGFR, or
oncogenic activation of one of its
presumptive downstream effectors,
the Ras protein, leads to increased
synthesis and secretion of a potent
angiogenic factor, vascular
endothelial growth factor (VEGF).
VEGF production in cancer can also
be elevated as a result of other gene
defects, such as the inactivation of
the von Hippel–Lindau (VHL)
tumor suppressor gene. The loss of
angiostatic factors is also critical in
cancer-associated angiogenesis, and
inactivation of the p53 gene may lead
to reduced expression of
thrombospondin, a powerful
angiostatic protein.
Matrix metalloproteases (MMPs)
have long been thought to have a
major role in the invasive and
metastatic properties of cancer,
presumably via the ability of MMPs
to break down extracellular matrix
physical barriers. MMPs may also
contribute to the successful initial
growth of pre-cancerous and
cancerous cells at the primary tumor
site, as well as the subsequent
growth of cancer in distant organs
following its metastatic spread. This
could be due to the diverse activities
of many MMPs, including their
ability to cleave various growth
factors, growth factor receptors, and
cell–cell adhesion molecules. Recent
work suggests increased expression
of MMP-7 (also called matrilysin) in
cancer, can result from mutational
inactivation of the APC tumor
suppressor or mutational activation of
β-catenin. Moreover, it seems likely
that the link between MMP-7
expression and APC or β-catenin
defects is not a singular example, and
other signaling networks with direct
roles in regulating MMP expression
in cancer remain to be uncovered.
Future directions
In the past, progress in rigorously
defining critical factors that underlie
tumor progression has been limited
by the often ineffectual experimental
systems available and the largely
descriptive and correlative data
obtained in many studies.
Substantial advances have been
made recently, including the
development of robust methods for
gene transfer and in vitro
manipulation of the genomes of
normal, pre-cancerous and cancerous
cells; the generation of new
transgenic and knockout mouse
models and normal and cancer cell
lines derived from these genetically
defined mice; and the development
of comprehensive and rapid
methodologies, such as cDNA and
oligonucleotide arrays, for defining
the gene expression changes
attributable to specific defects in
cancer. Future studies will combine
these and other strategies to
rigorously determine the specific
array of mutations and gene
expression changes in cancer cells,
and the means by which the gene
defects contribute to the successful
initiation of a pre-cancerous clone
and its subsequent progression to a
fully invasive and metastatic cancer.
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